Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Multi-Center, Open-Label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Trial Profile

A Phase III Multi-Center, Open-Label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2019

At a glance

  • Drugs Nilotinib (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ENESTnd
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 19 Dec 2018 This trial has been completed in Czech Republic .
    • 06 Dec 2018 Planned End Date changed from 12 Nov 2018 to 31 Dec 2018.
    • 04 Dec 2018 Results of an Indirect Comparison between Bosutinib, Nilotinib and Dasatinib in First-Line Chronic Phase CML using data from ENESTnd, DASISION and BFORE trials, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top